Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new ...

Semaglutide sells for $997 a month when branded under Ozempic and $1,349 a month for Wegovy. The haircut to Ozempic may have a spillover effect on competitor drugs from Eli Lilly — Mounjaro and ...

The brand name for the anti-diabetes compound semaglutide has broken all records by becoming one of the most profitable and ...

In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

Golden Globe Awards, many celebrities showcased dramatic physical transformations, leading to speculation about the use of ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...